Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
Indirect comparison of linvoseltamab versus selinexor plus dexamethasone for penta-exposed relapsed/refractory multiple myeloma (RRMM)
Hans C. Lee, MD
Associate Professor & Director, Multiple Myeloma Clinical Research
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Houston, Texas, United States